189 related articles for article (PubMed ID: 21651941)
1. Vaccine stabilization: research, commercialization, and potential impact.
Kristensen D; Chen D; Cummings R
Vaccine; 2011 Sep; 29(41):7122-4. PubMed ID: 21651941
[TBL] [Abstract][Full Text] [Related]
2. Opportunities and challenges of developing thermostable vaccines.
Chen D; Kristensen D
Expert Rev Vaccines; 2009 May; 8(5):547-57. PubMed ID: 19397412
[TBL] [Abstract][Full Text] [Related]
3. Exposure to heat and freezing in the vaccine cold chain in Thailand.
Techathawat S; Varinsathien P; Rasdjarmrearnsook A; Tharmaphornpilas P
Vaccine; 2007 Jan; 25(7):1328-33. PubMed ID: 17157419
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.
Nelson CM; Wibisono H; Purwanto H; Mansyur I; Moniaga V; Widjaya A
Bull World Health Organ; 2004 Feb; 82(2):99-105. PubMed ID: 15042231
[TBL] [Abstract][Full Text] [Related]
5. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
[TBL] [Abstract][Full Text] [Related]
6. Vaccine process technology.
Josefsberg JO; Buckland B
Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
[TBL] [Abstract][Full Text] [Related]
7. Spray drying and vaccine stabilization.
McAdams D; Chen D; Kristensen D
Expert Rev Vaccines; 2012 Oct; 11(10):1211-9. PubMed ID: 23176654
[TBL] [Abstract][Full Text] [Related]
8. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants.
Braun LJ; Tyagi A; Perkins S; Carpenter J; Sylvester D; Guy M; Kristensen D; Chen D
Vaccine; 2009 Jan; 27(1):72-9. PubMed ID: 18973782
[TBL] [Abstract][Full Text] [Related]
9. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
Collin N; Dubois PM
Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
[TBL] [Abstract][Full Text] [Related]
10. Formulation, stability, and delivery of live attenuated vaccines for human use.
Burke CJ; Hsu TA; Volkin DB
Crit Rev Ther Drug Carrier Syst; 1999; 16(1):1-83. PubMed ID: 10099898
[TBL] [Abstract][Full Text] [Related]
11. Advances in vaccine stability monitoring technology.
Zweig SE
Vaccine; 2006 Aug; 24(33-34):5977-85. PubMed ID: 16759766
[TBL] [Abstract][Full Text] [Related]
12. Vaccine provision: Delivering sustained & widespread use.
Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a thermostable hepatitis B vaccine formulation.
Braun LJ; Jezek J; Peterson S; Tyagi A; Perkins S; Sylvester D; Guy M; Lal M; Priddy S; Plzak H; Kristensen D; Chen D
Vaccine; 2009 Jul; 27(34):4609-14. PubMed ID: 19523912
[TBL] [Abstract][Full Text] [Related]
14. Vaccine manufacturing: challenges and solutions.
Ulmer JB; Valley U; Rappuoli R
Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
[TBL] [Abstract][Full Text] [Related]
15. Analysis of vaccine stability.
Volkin DB; Burke CJ; Sanyal G; Middaugh CR
Dev Biol Stand; 1996; 87():135-42. PubMed ID: 8854010
[TBL] [Abstract][Full Text] [Related]
16. Vaccines in the national immunization programme.
Bass AG
P N G Med J; 1993 Jun; 36(2):141-57. PubMed ID: 8154196
[TBL] [Abstract][Full Text] [Related]
17. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview.
Bahey-El-Din M
Vaccine; 2012 Jan; 30(4):685-90. PubMed ID: 22154771
[TBL] [Abstract][Full Text] [Related]
18. Innovative vaccine production technologies: the evolution and value of vaccine production technologies.
Bae K; Choi J; Jang Y; Ahn S; Hur B
Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962
[TBL] [Abstract][Full Text] [Related]
19. Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain.
Stewart M; Ward SJ; Drew J
Vaccine; 2014 May; 32(24):2931-8. PubMed ID: 24662703
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries.
Karp CL; Lans D; Esparza J; Edson EB; Owen KE; Wilson CB; Heaton PM; Levine OS; Rao R
Vaccine; 2015 Jul; 33(30):3471-9. PubMed ID: 26055297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
